Collegium Pharmaceutical Full Year 2024 Earnings: In Line With Expectations [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
Net income: US$69.2m (up 44% from FY 2023). Profit margin: 11% (up from 8.5% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$2.14 (up from US$1.43 in FY 2023). NasdaqGS:COLL Earnings and Revenue Growth March 1st 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Collegium Pharmaceutical Meets Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 8.5% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's share price is broadly unchanged from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 1 warning sign for Collegium Pharmaceutical that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in t
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
COLL
Earnings
- 11/6/25 - Beat
COLL
Sec Filings
- 12/17/25 - Form 144
- 12/10/25 - Form 4
- 12/9/25 - Form 4
- COLL's page on the SEC website